SI3083592T1 - Substituirani piperidinil-tetrahidrokinolini in njihova uporaba kot antagonisti adrenoreceptorja alfa-2c - Google Patents

Substituirani piperidinil-tetrahidrokinolini in njihova uporaba kot antagonisti adrenoreceptorja alfa-2c

Info

Publication number
SI3083592T1
SI3083592T1 SI201430831T SI201430831T SI3083592T1 SI 3083592 T1 SI3083592 T1 SI 3083592T1 SI 201430831 T SI201430831 T SI 201430831T SI 201430831 T SI201430831 T SI 201430831T SI 3083592 T1 SI3083592 T1 SI 3083592T1
Authority
SI
Slovenia
Prior art keywords
tetrahydroquinolines
alpha
substituted piperidinyl
adrenoreceptor antagonists
adrenoreceptor
Prior art date
Application number
SI201430831T
Other languages
English (en)
Inventor
Eva Maria Becker-Pelster
Philipp Buchgraber
Anja Buchmuller
Karen Engel
Volker Geiss
Andreas Goller
Herbert Himmel
Raimund Kast
Andreas Knorr
Dieter Lang
Gorden Redlich
Carsten Schmeck
Hanna Tinel
Frank Wunder
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of SI3083592T1 publication Critical patent/SI3083592T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201430831T 2013-12-19 2014-12-16 Substituirani piperidinil-tetrahidrokinolini in njihova uporaba kot antagonisti adrenoreceptorja alfa-2c SI3083592T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13198385 2013-12-19
EP14192877 2014-11-12
EP14812245.0A EP3083592B1 (de) 2013-12-19 2014-12-16 Substituierte piperidinyl-tetrahydrochinoline und ihre verwendung als alpha-2c adrenorezeptor antagonisten
PCT/EP2014/077862 WO2015091414A2 (de) 2013-12-19 2014-12-16 Substituierte piperidinyl-tetrahydrochinoline

Publications (1)

Publication Number Publication Date
SI3083592T1 true SI3083592T1 (sl) 2018-09-28

Family

ID=52101341

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201430831T SI3083592T1 (sl) 2013-12-19 2014-12-16 Substituirani piperidinil-tetrahidrokinolini in njihova uporaba kot antagonisti adrenoreceptorja alfa-2c

Country Status (38)

Country Link
US (3) US9944621B2 (sl)
EP (2) EP3329920A3 (sl)
JP (2) JP6487922B2 (sl)
KR (1) KR20160098425A (sl)
CN (1) CN106458978B (sl)
AP (1) AP2016009276A0 (sl)
AU (2) AU2014364732B2 (sl)
BR (1) BR112016014008A2 (sl)
CA (1) CA2934108C (sl)
CL (1) CL2016001578A1 (sl)
CR (1) CR20160276A (sl)
CU (1) CU24390B1 (sl)
CY (1) CY1120701T1 (sl)
DK (1) DK3083592T3 (sl)
DO (1) DOP2016000149A (sl)
EA (1) EA032250B1 (sl)
ES (1) ES2689023T3 (sl)
HR (1) HRP20181536T1 (sl)
HU (1) HUE039942T2 (sl)
IL (1) IL246246B (sl)
JO (2) JOP20200052A1 (sl)
LT (1) LT3083592T (sl)
MX (1) MX365289B (sl)
MY (1) MY177393A (sl)
NI (1) NI201600084A (sl)
NZ (2) NZ758272A (sl)
PE (1) PE20160846A1 (sl)
PH (1) PH12016501190A1 (sl)
PL (1) PL3083592T3 (sl)
PT (1) PT3083592T (sl)
RS (1) RS57835B1 (sl)
SG (1) SG11201604978QA (sl)
SI (1) SI3083592T1 (sl)
TN (1) TN2016000250A1 (sl)
TW (1) TWI667234B (sl)
UA (1) UA120702C2 (sl)
UY (1) UY35887A (sl)
WO (1) WO2015091414A2 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
EP3373936A1 (en) 2015-11-13 2018-09-19 Bayer Pharma Aktiengesellschaft 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
WO2018197333A1 (en) 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
CN110917195A (zh) * 2018-08-20 2020-03-27 山西惠尔健生物科技有限公司 肌松剂阿库氯铵(Alcuronium chloride)可作为抗心律失常药物
CA3120152A1 (en) * 2018-11-20 2020-05-28 Bayer Aktiengesellschaft A2-adrenoceptor subtype c (alpha-2c) antagonists for the treatment of sleep apnea
WO2020165031A1 (de) 2019-02-15 2020-08-20 Bayer Aktiengesellschaft Substituierte isochinolin-piperidinylmethanon-derivate
WO2020182018A1 (zh) * 2019-03-12 2020-09-17 四川科伦博泰生物医药股份有限公司 氮杂环化合物、其制备方法及用途
TWI804119B (zh) * 2020-12-21 2023-06-01 大陸商上海濟煜醫藥科技有限公司 三氮唑類三并環衍生物及其製備方法和應用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100238346B1 (ko) 1993-04-07 2000-03-02 오쓰까 아끼히꼬 피페리딘 유도체를 유효성분으로 하는 말초혈관확장제
HUP9902056A3 (en) 1996-01-17 2002-02-28 Novo Nordisk As Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
US6294517B1 (en) * 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
EP1000066A1 (en) 1997-07-16 2000-05-17 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
DE19734557A1 (de) 1997-08-04 1999-02-11 Oliver Lang Netzanschlußloses Kleinleistungs-Haushaltsgerät
GB9808599D0 (en) * 1998-04-22 1998-06-24 Nycomed Imaging As Improvements in or realting to contrast agents
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
UA69420C2 (uk) 1998-10-06 2004-09-15 Янссен Фармацевтика Н.В. ТРИЦИКЛІЧНІ <font face="Symbol">D3</font>-ПІПЕРИДИНИ ЯК <font face="Symbol">a<sub></font>2</sub>-АНТАГОНІСТИ
HUP0203528A3 (en) 1999-05-04 2003-11-28 Schering Corp Piperidine derivatives useful as ccr5 antagonists, pharmaceutical compositions containing them and their use
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
FI20000480A0 (fi) * 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
US6444681B1 (en) 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
GB0108876D0 (en) 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
US20040110826A1 (en) * 2001-09-28 2004-06-10 Noriaki Uesaka Receptor Antagonists
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2004067513A1 (en) * 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
JP4757802B2 (ja) 2003-11-03 2011-08-24 シェーリング コーポレイション ケモカインレセプターの阻害剤として有用なビピペリジニル誘導体
GB0326992D0 (en) 2003-11-20 2003-12-24 Dawson Philip J Valve control system
CN1946402A (zh) 2004-02-05 2007-04-11 先灵公司 用作ccr3拮抗剂的哌啶衍生物
US20060223792A1 (en) 2005-03-31 2006-10-05 Butler Christopher R Phenyl and pyridyl LTA4H modulators
US7700592B2 (en) * 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
US8686051B2 (en) * 2007-01-29 2014-04-01 Vlife Sciences Technologies Pvt. Ltd. Pharmaceutical composition for treatment of diabetic complications
EP3050568B1 (en) 2007-03-13 2020-12-02 JDS Therapeutics, LLC Methods and compositions for the sustained release of chromium
US20110190247A1 (en) 2008-08-04 2011-08-04 Schering Corporation Cyclopropylchromene derivatives as modulators of the alpha-2c receptor
WO2010042475A1 (en) 2008-10-07 2010-04-15 Schering Corporation Spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
TW201024282A (en) 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
JP2012512834A (ja) * 2008-12-19 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症、喘息及びcopdの処置のためのccr2受容体アンタゴニストとしての環状ピリミジン−4−カルボキサミド
WO2011044229A1 (en) 2009-10-06 2011-04-14 Allergan, Inc. 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators
US20130210840A1 (en) 2010-06-11 2013-08-15 Imprimis Pharmaceuticals, Inc. Anti-Cellulite Composition and Method of Treating Cellulite
CN103547580B (zh) 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
US9624199B2 (en) * 2013-12-19 2017-04-18 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives
KR20160098424A (ko) * 2013-12-19 2016-08-18 바이엘 파마 악티엔게젤샤프트 치환된 피페리디닐-테트라히드로퀴놀린
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c

Also Published As

Publication number Publication date
BR112016014008A2 (pt) 2017-08-08
SG11201604978QA (en) 2016-07-28
JO3649B1 (ar) 2020-08-27
EP3329920A3 (de) 2019-01-09
AU2019202709B2 (en) 2020-10-22
MX365289B (es) 2019-05-29
US20180141931A1 (en) 2018-05-24
UY35887A (es) 2015-07-31
PL3083592T3 (pl) 2018-12-31
TN2016000250A1 (en) 2017-10-06
JP2019048875A (ja) 2019-03-28
JP6487922B2 (ja) 2019-03-20
UA120702C2 (uk) 2020-01-27
HUE039942T2 (hu) 2019-02-28
CN106458978B (zh) 2019-06-28
IL246246A0 (en) 2016-07-31
CU20160088A7 (es) 2016-10-28
PE20160846A1 (es) 2016-09-23
IL246246B (en) 2019-10-31
WO2015091414A3 (de) 2015-08-20
PT3083592T (pt) 2018-10-26
AU2014364732A1 (en) 2016-07-07
US20180141930A1 (en) 2018-05-24
CR20160276A (es) 2016-10-20
MX2016008113A (es) 2016-10-31
MY177393A (en) 2020-09-14
WO2015091414A2 (de) 2015-06-25
EP3329920A2 (de) 2018-06-06
TWI667234B (zh) 2019-08-01
CA2934108C (en) 2022-11-29
LT3083592T (lt) 2018-09-25
AU2014364732B2 (en) 2019-03-28
EA201600477A1 (ru) 2016-11-30
RS57835B1 (sr) 2018-12-31
NI201600084A (es) 2017-05-12
NZ758272A (en) 2021-11-26
AP2016009276A0 (en) 2016-06-30
CL2016001578A1 (es) 2017-01-13
HRP20181536T1 (hr) 2018-11-16
PH12016501190B1 (en) 2016-07-25
JOP20200052A1 (ar) 2017-06-16
US10323020B2 (en) 2019-06-18
NZ721374A (en) 2021-07-30
ES2689023T3 (es) 2018-11-08
CY1120701T1 (el) 2019-12-11
CA2934108A1 (en) 2015-06-25
DK3083592T3 (en) 2018-10-15
KR20160098425A (ko) 2016-08-18
EP3083592B1 (de) 2018-06-27
US10961221B2 (en) 2021-03-30
DOP2016000149A (es) 2016-07-15
CU24390B1 (es) 2019-04-04
AU2019202709A1 (en) 2019-05-16
TW201609701A (zh) 2016-03-16
US20160318901A1 (en) 2016-11-03
EA032250B1 (ru) 2019-04-30
PH12016501190A1 (en) 2016-07-25
EP3083592A2 (de) 2016-10-26
US9944621B2 (en) 2018-04-17
CN106458978A (zh) 2017-02-22
JP2017500321A (ja) 2017-01-05

Similar Documents

Publication Publication Date Title
HK1226301A1 (zh) 修飾的治療劑及其組合物
HK1223975A1 (zh) 含納米氣泡的組合物及其用途
EP2968304A4 (en) 4-PHENYLPIPERIDINES, PREPARATION THEREOF AND USE THEREOF
HK1203493A1 (en) Substituted azabicycles and use thereof
EP2968303A4 (en) OCTAHYDROCYCLOPENTAPYROLE AND THEIR PREPARATION AND USE
GB201320729D0 (en) Therapeutic compounds and their use
GB201317286D0 (en) Composition and Use
HRP20181536T1 (hr) Supstituirani piperidinil-tetrahidrokinolini i njihova uporaba kao antagonisti alfa-2c adrenoreceptora
EP2968474A4 (en) SKIN COMPOSITIONS AND USES
HK1220920A1 (zh) 治療性組合物和其用途
GB201305277D0 (en) Novel combination and use
IL240248A0 (en) Met-binding substances and their uses
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
EP2976091C0 (de) Antioxidativ wirksame zusammensetzung und deren verwendung
LT2956471T (lt) Il-1beta inhibitoriaus kompozicija ir jos naudojimas
GB201311361D0 (en) Compounds and their therapeutic use
GB201301979D0 (en) New composition and use thereof
GB201307989D0 (en) Novel combinations and use
GB201308736D0 (en) Compounds and their therapeutic use
IL240177A0 (en) Converted chromium-6-yloxy-cycloalkanes and their use as drugs
GB201305297D0 (en) Novel agents and uses thereof
GB201311272D0 (en) Anti-microbial agents and uses thereof
TH1601003662A (th) พิเพอริดินิลเตตระไฮโดรควิโนลีนที่ถูกแทนที่ และการใช้งานของพวกมันโดยเป็น แอลฟา-2c อะดรีโนรีเซพเตอร์ แอนทาโกนิสต์
GB201322467D0 (en) Composition and use
GB201313605D0 (en) Novel compounds and their use